Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4830650 | 0.89 | LMNA (0.37) | MEN1ALDH1A1KMT2AGRM5 | |
| SCHEMBL7493553 | 0.82 | HTR2A (0.33) | PNMTHTR2AHTR2CHTR2B | |
| SCHEMBL4830620 | 0.78 | HTR2A (0.57) | HTR2AHTR2CHTR2B | |
| SCHEMBL7501270 | 0.78 | HTR2A (0.57) | HTR2AHTR2CHTR2B | |
| Ammonia Solution, Strong SCHEMBL906002 | 0.71 | HTR2C (0.64) | MEN1ALDH1A1KMT2APNMTHTR2A | |
| Fumaric Acid SCHEMBL7543324 | 0.70 | LMNA (0.55) | MEN1KMT2AHTR2AHTR2CHTR2B | |
| Fumaric Acid SCHEMBL7543316 | 0.70 | LMNA (0.55) | MEN1KMT2AHTR2AHTR2CHTR2B | |
| Fumaric Acid SCHEMBL4830658 | 0.70 | LMNA (0.55) | MEN1KMT2AHTR2AHTR2CHTR2B | |
| Ammonia Solution, Strong SCHEMBL4829221 | 0.69 | HTR2C (0.65) | MEN1ALDH1A1KMT2APNMTHTR2A | |
| Ammonia Solution, Strong SCHEMBL4822367 | 0.68 | ALDH1A1 (0.41) | MEN1ALDH1A1KMT2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962939-B1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2005-11-08 | — | — | US | claimed |
| EP-1202964-B1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RES LTD (GB) | 2005-10-12 | — | — | EP | claimed |
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-29 | — | — | US | disclosed |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-15 | — | — | US | disclosed |
| US-20080090858-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-7323473-B2 | Administering (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine; serotonin receptor antagonists (5HT/5HT2C) for treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323487-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323486-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| US-20070099980-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| US-7166632-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166613-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-6962939-B1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2005-11-08 | — | — | US | disclosed |
| EP-1202964-B1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RES LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-08 | — | — | US | disclosed |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-01 | — | — | US | disclosed |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-08-25 | — | — | US | disclosed |
| EP-1202964-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012602-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090858-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | MEN1 765/4885ALDH1A1 1748/4885KMT2A 1337/4885 |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | MEN1 765/4885ALDH1A1 1748/4885KMT2A 1337/4885 |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | MEN1 765/4885ALDH1A1 1748/4885KMT2A 1337/4885 |
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | HTR2C, HTR2A, HTR1A | MEN1 763/4885ALDH1A1 1741/4885KMT2A 1332/4885 |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | MEN1 765/4885ALDH1A1 1748/4885KMT2A 1337/4885 |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | HTR2C, HTR2A, HTR1A | MEN1 765/4885ALDH1A1 1748/4885KMT2A 1337/4885 |
| US-20070099980-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | MEN1 765/4885ALDH1A1 1748/4885KMT2A 1337/4885 |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | HTR2C, HTR2A, HTR5A | MEN1 1151/4885ALDH1A1 1407/4885KMT2A 1174/4885 |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | MEN1 765/4885ALDH1A1 1748/4885KMT2A 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.